Firm News

Home 9 News Item 9 Wiggin and Dana Represents Client Rallybio In Its Acquisition of Two Orphan Drug Programs From Prophylix AS

Wiggin and Dana Represents Client Rallybio In Its Acquisition of Two Orphan Drug Programs From Prophylix AS

August 22, 2019

On behalf of the Firm, Wiggin and Dana Partners Evan Kipperman and Patti Melick represented Rallybio, LLC in its acquisition of two orphan drug programs, NAITgam and a follow-on therapy, from Prophylix AS for the treatment of fetal and neonatal alloimmune thrombocytopenia (FNAIT), a potentially disabling or life-threatening disorder in fetuses and newborns.

To learn more, click here.

Resources

Related People

Related Services

Firm Highlights